123I-MIBG cardiac uptake, smell identification and 123I-FP-CIT SPECT in the differential diagnosis between vascular parkinsonism and Parkinson's disease

Navarro‐Otano, Judith; Gaig, Carles; Muxí, África; Lomeña, Francisco; Compta, Yaroslau; Buongiorno, Maríateresa; Martí, María‐José; Tolosa, Eduardo; Valldeoriola, Francesc

doi:10.1016/j.parkreldis.2013.10.025

Cited by 31 publications

(29 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Kikuchi et al [7] reported that the sensitivity and specificity in discriminating PD patients from MSA patients were 85.71% and 76.20% for cardiac MIBG scintigraphy (with a H/M ratio cut-off value of 1.795) and 73.81% and 85.71% for olfactory testing. Reduced cardiac MIBG uptake and olfactory impairment assessed by the University of Pennsylvania Smell Identification Test has also been reported to assist the differential diagnosis between vascular parkinsonism and PD [28]. …”

Section: Discussionmentioning

confidence: 99%

Usefulness of Cardiac MIBG Scintigraphy, Olfactory Testing and Substantia Nigra Hyperechogenicity as Additional Diagnostic Markers for Distinguishing between Parkinson’s Disease and Atypical Parkinsonian Syndromes

et al. 2016

View full text Add to dashboard Cite

BackgroundWe aimed to evaluate the utility of the combined use of cardiac 123I-metaiodobenzylguanidine (MIBG) scintigraphy, olfactory testing, and substantia nigra (SN) hyperechogenicity on transcranial sonography (TCS) in differentiating Parkinson’s disease (PD) from atypical parkinsonian syndromes (APSs), such as multiple system atrophy (MSA) and progressive supranuclear palsy (PSP).MethodsCardiac MIBG scintigraphy, card-type odor identification testing (Open Essence (OE), Wako, Japan), and TCS were performed with 101 patients with PD and 38 patients with APSs (MSA and PSP). Receiver operating characteristic (ROC) curve analysis was used to assess the sensitivity and specificity of these batteries for diagnosing PD from APSs. The diagnostic accuracy of the three tests was also assessed among patients at the early disease stage (drug-naïve patients with a disease duration of 3 years or less).ResultsIn differentiating PD from APSs, the area under the ROC curve was 0.74 (95% CI, 0.65–0.83), 0.8 (95% CI, 0.73–0.87), and 0.75 (95% CI, 0.67–0.82) for TCS, cardiac MIBG scintigraphy, and olfactory testing, respectively. The diagnostic sensitivity and specificity were 53.1% and 91.7%, respectively, for TCS, 70.3% and 86.8%, respectively, for cardiac MIBG scintigraphy, 58.4% and 76.3%, respectively, for OE. Among early-stage patients, sensitivity and specificity were 50.0% and 93.8%, respectively, for TCS, 57.1% and 87.5%, respectively, for cardiac MIBG scintigraphy, and 54.8% and 79.2%, respectively, for OE. At least one positive result from 3 tests improved sensitivity (86.1%) but decreased specificity (63.2%). In contrast, at least 2 positive results from 3 tests had good discrimination for both early-stage patients (50.0% sensitivity and 93.8% specificity) and patients overall (57.8% sensitivity and 95.8% specificity). Positive results for all 3 tests yielded 100% specificity but low sensitivity (25%).ConclusionsAt least 2 positive results from among TCS, cardiac MIBG scintigraphy, and olfactory testing can support clinical diagnosis in distinguishing PD from APSs.

show abstract

Section: Discussionmentioning

confidence: 99%

Usefulness of Cardiac MIBG Scintigraphy, Olfactory Testing and Substantia Nigra Hyperechogenicity as Additional Diagnostic Markers for Distinguishing between Parkinson’s Disease and Atypical Parkinsonian Syndromes

et al. 2016

View full text Add to dashboard Cite

show abstract

“…70,71 In the PREDICT-PD study, Noyce et al developed an algorithm for estimating the risk of developing PD. Based on results from systematic review of the literature, they included three of the strongest risk markers of PD, which were olfactory dysfunction (UPSIT), REM sleep behavior disorder (RBD), and finger tapping speed.…”

Section: Smell Identification As a Combined Biomarkermentioning

confidence: 99%

Spotlight on olfactory dysfunction in Parkinson's disease

Rodríguez-Violante¹,

Ospina-García²,

Perez‐Lohman³

et al. 2017

JPRLS

View full text Add to dashboard Cite

“…[1][2][3][4][5][6][7][8][9][10][11][12][13][14] The amount of free radio iodide is the most important radiochemical impurity and must be limited to prevent excessive thyroid uptake. The amount of free iodide should be \1%-2% of total radioactivity.…”

Section: Introductionmentioning

confidence: 99%

1-23I-MIBG thyroid uptake: Implications for MIBG imaging of the heart

Giubbini

Milan

Marcassa

et al. 2016

Journal of Nuclear Cardiology

View full text Add to dashboard Cite

The thyroid visualization in MIBG imaging is likely an expression of thyroid sympathetic innervation. The differences in TWO and T/M ratio in cardiac and neurological patients probably express differences in thyroid dopaminergic receptors. Thus, pre-treatment with potassium perchlorate or Lugol's solution may not be justified in patients undergoing 123I-MIBG imaging in whom the risk of side effects due to pre-treatment could be higher than the risk due to thyroid radiation exposure.

show abstract

123I-MIBG cardiac uptake, smell identification and 123I-FP-CIT SPECT in the differential diagnosis between vascular parkinsonism and Parkinson's disease

Cited by 31 publications

References 25 publications

Usefulness of Cardiac MIBG Scintigraphy, Olfactory Testing and Substantia Nigra Hyperechogenicity as Additional Diagnostic Markers for Distinguishing between Parkinson’s Disease and Atypical Parkinsonian Syndromes

Usefulness of Cardiac MIBG Scintigraphy, Olfactory Testing and Substantia Nigra Hyperechogenicity as Additional Diagnostic Markers for Distinguishing between Parkinson’s Disease and Atypical Parkinsonian Syndromes

Spotlight on olfactory dysfunction in Parkinson's disease

1-23I-MIBG thyroid uptake: Implications for MIBG imaging of the heart

Contact Info

Product

Resources

About

123I-MIBG cardiac uptake, smell identification and 123I-FP-CIT SPECT in the differential diagnosis between vascular parkinsonism and Parkinson's disease

Cited by 31 publications

References 25 publications

Usefulness of Cardiac MIBG Scintigraphy, Olfactory Testing and Substantia Nigra Hyperechogenicity as Additional Diagnostic Markers for Distinguishing between Parkinson’s Disease and Atypical Parkinsonian Syndromes

Usefulness of Cardiac MIBG Scintigraphy, Olfactory Testing and Substantia Nigra Hyperechogenicity as Additional Diagnostic Markers for Distinguishing between Parkinson’s Disease and Atypical Parkinsonian Syndromes

Spotlight on olfactory dysfunction in Parkinson&#39;s disease

1-23I-MIBG thyroid uptake: Implications for MIBG imaging of the heart

Contact Info

Product

Resources

About

Spotlight on olfactory dysfunction in Parkinson's disease